دورية أكاديمية
أعرض في EDS

NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.

التفاصيل البيبلوغرافية
العنوان: NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.
المؤلفون: Vegliante MC; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Mazzara S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Zaccaria GM; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Esposito F; Department of Mathematics, University of Bari Aldo Moro, Bari, Italy.; INDAM-GNCS Research Group, Rome, Italy., Melle F; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Motta G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Sapienza MR; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Opinto G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Volpe G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Bucci A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Gargano G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.; INDAM-GNCS Research Group, Rome, Italy., Enjuanes A; Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain., Tabanelli V; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Fiori S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Minoia C; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Clemente F; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Negri A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Gulino A; Cogentech srl Società Benefit, FIRC Institute of Molecular Oncology (IFOM), Milan, Italy., Morello G; Department of Health Sciences, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy., Scattone A; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Zito AF; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Tommasi S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Agostinelli C; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Vitolo U; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Chiappella A; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Barbui AM; Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Derenzini E; Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy.; Department of Health Sciences, University of Milan, Milan, Italy., Zinzani PL; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Casadei B; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.; Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Rivas-Delgado A; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain., López-Guillermo A; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain., Campo E; CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona; University of Barcelona, Barcelona, Spain., Moschetta A; Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy., Guarini A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy., Pileri SA; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy., Ciavarella S; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
المصدر: Hematological oncology [Hematol Oncol] 2022 Dec; Vol. 40 (5), pp. 864-875. Date of Electronic Publication: 2022 Aug 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, England : Wiley-Blackwell, c1983-
مواضيع طبية MeSH: Lymphoma, Large B-Cell, Diffuse*/drug therapy , Lymphoma, Large B-Cell, Diffuse*/genetics, Humans ; Tumor Microenvironment ; Liver X Receptors/genetics
مستخلص: The role of macrophages (Mo) and their prognostic impact in diffuse large B-cell lymphomas (DLBCL) remain controversial. By regulating the lipid metabolism, Liver-X-Receptors (LXRs) control Mo polarization/inflammatory response, and their pharmacological modulation is under clinical investigation to treat human cancers, including lymphomas. Herein, we surveyed the role of LXRs in DLBCL for prognostic purposes. Comparing bulk tumors with purified malignant and normal B-cells, we found an intriguing association of NR1H3, encoding for the LXR-α isoform, with the tumor microenvironment (TME). CIBERSORTx-based purification on large DLBCL datasets revealed a high expression of the receptor transcript in M1-like pro-inflammatory Mo. By determining an expression cut-off of NR1H3, we used digital measurement to validate its prognostic capacity on two large independent on-trial and real-world cohorts. Independently of classical prognosticators, NR1H3 high patients displayed longer survival compared with NR1H3 low cases and a high-resolution Mo GEP dissection suggested a remarkable transcriptional divergence between subgroups. Overall, our findings indicate NR1H3 as a Mo-related biomarker identifying patients at higher risk and prompt future preclinical studies investigating its mouldability for therapeutic purposes.
(© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
References: J Clin Oncol. 2015 Apr 20;33(12):1379-88. (PMID: 25800755)
Leuk Lymphoma. 2014 Nov;55(11):2466-76. (PMID: 24397616)
Hematol Oncol. 2022 Dec;40(5):864-875. (PMID: 35850118)
Sci Transl Med. 2015 Apr 8;7(282):282ra47. (PMID: 25855493)
J Exp Med. 2013 Aug 26;210(9):1711-28. (PMID: 23897983)
Clin Cancer Res. 2017 May 1;23(9):2232-2244. (PMID: 27923841)
Nature. 2008 Jul 24;454(7203):470-7. (PMID: 18650918)
Nucleic Acids Res. 2013 Apr 1;41(6):3518-31. (PMID: 23393188)
J Exp Med. 2016 Jan 11;213(1):15-23. (PMID: 26694970)
Blood. 2022 Jan 13;139(2):165-176. (PMID: 34610110)
Cell Metab. 2015 Apr 7;21(4):517-26. (PMID: 25863245)
J Clin Oncol. 2016 Nov 20;34(33):4015-4022. (PMID: 28199143)
J Clin Oncol. 2019 Jan 20;37(3):202-212. (PMID: 30523719)
Lancet Oncol. 2017 Aug;18(8):1076-1088. (PMID: 28668386)
Nat Med. 2018 May;24(5):679-690. (PMID: 29713087)
J Invest Dermatol. 2009 Apr;129(4):1016-25. (PMID: 18843292)
Circ Res. 2007 Jul 6;101(1):40-9. (PMID: 17540978)
PLoS One. 2017 Sep 19;12(9):e0184985. (PMID: 28926619)
Cancer Cell. 2021 Oct 11;39(10):1361-1374.e9. (PMID: 34478639)
Annu Rev Cell Dev Biol. 2000;16:459-81. (PMID: 11031244)
Ann Oncol. 2021 Nov;32(11):1400-1409. (PMID: 34438040)
N Engl J Med. 2018 Apr 12;378(15):1396-1407. (PMID: 29641966)
Blood. 2013 Aug 15;122(7):1256-65. (PMID: 23699601)
Cell. 2018 Feb 8;172(4):825-840.e18. (PMID: 29336888)
Leukemia. 2020 Feb;34(2):543-552. (PMID: 31530861)
Hematol Oncol. 2015 Jun;33(2):110-2. (PMID: 24711044)
N Engl J Med. 2008 Nov 27;359(22):2313-23. (PMID: 19038878)
Cancer Cell. 2012 Sep 11;22(3):359-72. (PMID: 22975378)
Blood. 2010 Nov 18;116(20):e81-9. (PMID: 20610814)
Haematologica. 2015 Feb;100(2):238-45. (PMID: 25381134)
Science. 2013 Nov 29;342(6162):1094-8. (PMID: 24288332)
Hepatogastroenterology. 2008 Nov-Dec;55(88):2016-27. (PMID: 19260470)
Cell Death Differ. 2014 Dec;21(12):1914-24. (PMID: 25124554)
Cell. 2017 Oct 5;171(2):481-494.e15. (PMID: 28985567)
FASEB J. 2019 Aug;33(8):9489-9504. (PMID: 31125275)
Cancer Discov. 2021 Jun;11(6):1468-1489. (PMID: 33541860)
Front Immunol. 2020 Nov 03;11:584303. (PMID: 33224146)
Histopathology. 2012 Jan;60(2):313-9. (PMID: 22211289)
Cell. 2014 Feb 27;156(5):986-1001. (PMID: 24581497)
Ann Oncol. 2018 Dec 1;29(12):2363-2370. (PMID: 30307529)
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10. (PMID: 34597589)
معلومات مُعتمدة: Italian Ministry of Health - "Ricerca Corrente"; Associazione Italiana per la Ricerca sul Cancro (AIRC)
فهرسة مساهمة: Keywords: deconvolution; diffuse large B-cell lymphoma; gene expression profiling; liver X receptors; microenvironment
المشرفين على المادة: 0 (NR1H3 protein, human)
0 (Liver X Receptors)
تواريخ الأحداث: Date Created: 20220719 Date Completed: 20221215 Latest Revision: 20230413
رمز التحديث: 20230413
مُعرف محوري في PubMed: PMC10087298
DOI: 10.1002/hon.3050
PMID: 35850118
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-1069
DOI:10.1002/hon.3050